"目錄號(hào): HY-13895
EpigeneticsStem Cell/WntJAK/STAT SignalingProtein Tyrosine Kinase/RTK-
WHI-P154是JAK3抑制劑，IC50為1.8 μM扳缕，還能抑制EGFR仇箱，Src挺勿，Abl，VEGFR和MAPK王暗，對(duì)JAK1和JAK2無(wú)活性。
相關(guān)產(chǎn)品
Sorafenib-Ruxolitinib-BIBF 1120-SU5416-Regorafenib-Ponatinib-Sunitinib-Cabozantinib-Baricitinib-Tofacitinib citrate-Vandetanib-Lenvatinib-Apatinib-Pazopanib-AZD-1480-
生物活性
Description
WHI-P154 is a potent JAK3 inhibitor with IC50 of 1.8 μM, no activity against JAK1 or JAK2, also inhibits EGFR, Src, Abl, VEGFR and MAPK, prevents Stat3, but not Stat5 phosphorylation.IC50 Value: 1.8 uM (JAK3); 4 nM(EGFR);100 nM(VEGFR) [1]Target: JAK3; VEGFR/EGFRin vitro: WHI-P154 is first described as a JAK3 inhibitor that displays no activity at JAK1 or JAK2. WHI-P154 inhibits STAT1 activation, iNOS expression and NO production in macrophages in vitro. But it is proved that WHI-P154 also inhibits other common kinases including EGFR, Src, Abl, VEGFR, MAPK and PI3-K and induces apoptosis in human glioblastoma cell lines [1]. inhibitor WHI-P154 decreased IFN-gamma-induced nuclear levels of signal transducer and activator of transcription 1alpha (STAT1alpha). JAK inhibitor WHI-P154 decreased also iNOS protein and mRNA expression and NO production in a concentration-dependent manner [2]. WHI-P154) exhibited significant cytotoxicity against U373 and U87 human glioblastoma cell lines, causing apoptotic cell death at micromolar concentrations. In vitro treatment with EGF-P154 resulted in killing of glioblastoma cells at nanomolar concentrations with an IC50 of 813 +/- 139 nM, whereas no cytotoxicity against EGF-R-negative leukemia cells was observed, even at concentrations as high as 100 microM [3].in vivo: The in vivo administration of EGF-P154 resulted in delayed tumor progression and improved tumor-free survival in a severe combined immunodeficient mouse glioblastoma xenograft model. Whereas none of the control mice remained alive tumor-free beyond 33 days (median tumor-free survival, 19 days) and all control mice had tumors that rapidly progressed to reach an average size of > 500 mm3 by 58 days, 40% of mice treated for 10 consecutive days with 1 mg/kg/day EGF-P154 remained alive and free of detectable tumors for more than 58 days with a median tumor-free survival of 40 days. The tumors developing in the remaining 60% of the mice never reached a size > 50 mm3 [3].
References
[3].Changelian PS, et al. The specificity of JAK3 kinase inhibitors. Blood. 2008 Feb 15;111(4):2155-7.
